Revive Therapeutics Ltd
Research Revive Therapeutics Ltd (31R) on Bullrun: market cap EUR 4.79M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker31R
- ExchangeF
- CountryCanada
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 4.79M
- Financial periodQ1 2026
- RevenueCAD 0
- Net income-CAD 506.51K
- Free cash flow-CAD 218
Valuation Snapshot
latest market cap is EUR 4.79M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CAD 0 | -CAD 10.69M | -CAD 230.48K | n/a | n/a | CAD 12.88K | CAD 69.49K | -CAD 3.74M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | EUR 4.79M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Revive Therapeutics Ltd
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Revive Therapeutics Ltd's market cap?
Revive Therapeutics Ltd's market capitalization is EUR 4.79M.
What does Revive Therapeutics Ltd do?
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks.